Vor Biopharma Inc

VOR

Healthcare|Biotechnology|USA

$19.14

-0.61 (-3.09%)

Earnings Power

$10.66

About

Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.

Stock Price

-58.6%(1Y)

Pipeline Summary

7 total trials

Phase 1

Phase 2

Phase 3

Phase 4

Withdrawn: 1Terminated: 4Recruiting: 2

Active Trials (2)

Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease

NCT07404865Primary Sjogren's Disease

Phase 3Recruiting

Enrollment: 250 participants

A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)

NCT06456580Generalized Myasthenia Gravis

Phase 3Recruiting

Enrollment: 180 participants

BioScore

4.5/10

Cautious